Locations:
Search IconSearch

News & Insight

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight

Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight

Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight

Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight

Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

outreach to underserved communities
June 2, 2023/Cancer/News & Insight

Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

prostate cancer

Lutetium-PSMA for Metastatic Prostate Cancer (Podcast)

FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer

22-CNR-3083315-CQD-Hero-650×450 gaining trust
July 20, 2022/Cancer/News & Insight

Building Trust is a Matter of Life and Death

The cornerstone of a successful doctor-patient relationship

22-CNR-2977865-CQD-Hero-650×450
June 28, 2022/Cancer/News & Insight

The Subjective Nature of “Safe and Tolerable” Conclusions

Dr. Aaron Gerds argues for more balance in safety reporting

BackPage 1 of 23Next

Advertisement

Ad